Introduction
Expression of human immunodeficiency virus type 1 (HIV-1) is controlled by cellular and viral factors that bind to the regulatory sequences present in both the proviral LTR and in the untranslated leader sequence of viral RNAs. The activation of viral transcription by the virus-encoded Tat protein occurs through the binding of this protein to the TAR region present in all viral mRNAs (Cullen & Greene, 1989; Hauber & Cullen, 1988; Muesing et al., 1987; Rosen et al., 1985) , whereas the DNA elements present in the promoter region of HIV-1 long terminal repeat (LTR), such as tcB enhancer (Nabel & Baltimore, 1987; Baeuerle, 1991) , play a major role in the activation of the promoter by cellular factors. Additional tuning of a transcriptional response is achieved through interaction of accessory proteins NFAT, LBP-1, HLP-1 and TCF-1 with the respective DNA binding sequences (Shaw et al., 1988; Wu et al., 1988; Vlach & Pitha, 1992a; Jones et al., 1988; Smith & Greene, 1989; Garcia et al., 1987; Li et al., 1991) . The expression driven by HIV-1 LTR is highly inducible by various extracellular factors such as cytokines, phorbol esters, antigens and heterologous viruses, and the most common element conferring the responsiveness of HIV-1 LTR to these stimuli is tcB enhancer, although other elements may also play a role (for review, see Pavlakis & Felber, 1990 ).
The polar drug hexamethylene bisacetamide (HMBA) has been used in studies exploring the process of differentiation of murine erythroleukaemia cells (MELC) (for review, see Marks & Rifkind, 1989) . Although the events accompanying the HMBA-mediated differentiation of these cells are not clear yet, it has been established that this inducer mediates a number of cellular changes, such as activation in calcium and potassium flux (Bridges et al., 1981) , transient increase in cAMP concentration (Gazitt et al., 1978) , and increase in membrane-associated protein kinase C activity (Melloni et al., 1987) . Also, changes in the expression of several cellular genes such as proto-oncogenes (c-myb, c-myc, c-fos and p53) and induction of expression of globin genes were observed in HMBA-treated cells (Lachman et al., 1984; Ramsay et al., 1986; Campbell et al., 1990) . Interestingly, treatment with HMBA also facilitated reactivation of herpes virus simplex types 1 (HSV-1) and 2 in animal latency models (Whitby et al., 1987; Bernstein et al., 1988; Leib et al., 1989) , and it appears that, in this system, HMBA activates HSV-1 by stimulating the expression of the immediate early (IE) genes of HSV-1 (McFarlane et al., 1992) . Because of its antiproliferative activity, HMBA has also been used as an anticancer agent (Marks & Rifkind, 1989) .
We have previously shown that latent HIV-1 provirus can be activated by several agents through the induction of binding of NF-KB proteins (Vlach & Pitha, 1992b) and also by HSV-1 infection through induction of proteins interacting with xB enhancer and leader region of HIV-1 LTR (Vlach & Pitha, 1992a) . Since HMBA has been shown to activate latent HSV-1, the aim of this study was to determine whether HMBA can also stimulate the expression of a latent HIV-1 provirus in cells of T lymphocytic and monocytic origin. We have found that HMBA causes rapid activation of HIV-1 transcription in both of these cell lines. The minimal HIV-1 promoter and the Spl sites were found to be necessary for the HMBA-mediated activation. However, HMBA treatment did not induce any detectable changes in the binding pattern of nuclear proteins to the enhancer and leader sequence of HIV-1 LTR. These results indicate that, in contrast to extracellular inducers, such as phorbol-12-myristate-13-acetate (PMA), tumour necrosis factor-~ (TNF~), and HSV-1 infection, HMBAmediated induction of HIV-1 LTR is not associated with an increased binding of NF-~cB-specific proteins or protein(s) binding to the LPB-1 site in the leader sequence of HIV-1 LTR. We conclude, therefore, that the activation of HIV-1 transcription by HMBA is caused by secondary modification of components of the basal transcription complex.
Methods
Cells and transfections. The T lymphocytic cell lines A3.01 (Folks et al., 1985) , ACH-2 (Clouse et al., 1989) , CEMR7/neo (Feinberg et al., 1991) , as well as the promonocytic cell line U1 (Folks et al., 1988) were grown in RPMI medium, supplemented with 10 % fetal bovine serum, L-glutamine and antibiotics.
In the transient transfection assays, cells (1 x 107) were transfected with 4 gg of reporter plasmid using either the electroporation technique or DEAE~lextran procedure (Vlach & Pitha, 1992a) . At 24 h after transfection, cells were either treated with HMBA or PMA, or infected with HSV-1, for 16 h, as indicated in individual experiments. Cells were then washed twice with PBS, lysed by three freeze-thaw cycles and chloramphenicol acetyltransferase (CAT) activity was assayed as described (Vlach & Pitha, 1992a) .
Plasmids. The HIV-1 LTR CAT plasmid and its deletion mutants HIV(104)CAT and HIV(57)CAT were obtained from Dr C. Rosen (Mosca et al., 1987) . Plasmid HIV(83)CAT was the kind gift of Dr M. Green (Southgate & Green, 1991) . pABtkCAT plasmid containing NF-KB sequences of HIV-1 LTR in the pBLCAT2 vector (Luckow & Schutz, 1987 ) was a gift from Dr S. Tong (Tong-Starksen et al., 1987) . Plasmid p23tkCAT is a derivative of pBLCAT2 containing NF-KB and LBP-1 binding sequences of HIV-1 LTR in front of the minimal thymidine kinase (tk) promoter (Vlach & Pitha, 1992a) . The pSP1CAT1 reporter plasmid containing the Spl binding sites of HIV-1 LTR -80 to -38 in front of the minimal tk promoter was prepared as follows. The fragment spanning the region of HIV-1 LTR between nucleotides (nt) -80 to + 80 was amplified by PCR, cleaved with DdeI, and blunt-ended with Klenow polymerase. The 42 bp fragment was then cloned into a blunt-ended XbaI site of the pBLCAT2 vector. The pSV2CAT contains a simian virus 40 (SV40) promoter region 5' of the CAT gene (Gorman et aL, 1982) . The ICPOCAT and ICP4CAT plasmids contain promoter/enhancer elements from the HSV-1 ICPO and ICP4 genes, respectively, cloned in front of CAT (Roberts et al., 1988) . The c-myc probe (from the ATCC) containing the first exon of human c-myc was a gift from Dr Paul Celano (Johns Hopkins University). The actin probe was the gift of Dr Tom Maniatis. Construction of the p4TAR30 riboprobe containing an 80 bp long fragment of the HIV-1 genome spanning the sequences between the cap site and + 80 nt (HindIII site) will be described elsewhere (J. Vlach & P. M. Pitha, unpublished results) .
Gel shift and Western blot analyses. Preparation of nuclear extracts used for binding analyses was described recently (Vlach & Pitha, 1992b) . The probes corresponding to the negative regulatory element (nt -342 to -139), enhancer region (nt -139 to -38), leader region (nt -4 to +80) and Spl sites (nt -80 to -38) of HIV-1 LTR were prepared by digestion of cloned HIV-1 LTR with appropriate restriction enzymes and labelling of the isolated fragments with Klenow polymerase and [32P]deoxynucleotides (Amersham).
Analysis of HIV-1 proteins by Western blot analysis was performed as described (Vlach & Pitha, 1992b) .
Northern blotting and $1 nuclease analysis. Total cellular RNA was isolated by the acid-phenol method (Chomczynski & Sacchi, 1987) and Northern hybridization was performed as described (Vlach & Pitha, 1992b) . For S1 nuclease analysis, 2 gg of total RNA was hybridized overnight with HIV-1 riboprobe (p4TAR30) (400000 c.p.m.) at 50 °C in buffer containing 40 mM-PIPES pH 6.5, 0.4 M-NaCI, 1 mM-EDTA and 80% formamide. Then S1 nuclease (in 0.28M-NaC1, 50mM-sodium acetate pH 4.5 and 4.5 mM-ZnSO4) was added and the reaction proceeded for 40 min at 37 °C. After ethanol precipitation of the RNA, the samples Were electrophoresed through an 8 % sequencing gel.
Results

HMBA can activate the latent HIV-1 provirus
In this study, we wished to determine whether HMBA, which has been shown to activate expression of several cellular genes, as well as the latent HSV-1, can also activate the latent, poorly expressed HIV-1 provirus. We used three cell lines containing integrated HIV-1 provirus: ACH-2 cells, a T lymphocytic cell line containing a single copy of HIV-1 provirus; CEMR7/neo cells, T lymphocytic cells carrying the tat-defective HIV-1 provirus (tat gene contains a mutation in the initiation codon and a linker insertion that prevents its translation) and finally U 1 cells which have monocytic characteristics and contain two copies of HIV-1 provirus. In all these three cells lines, HIV-1 provirus is only poorly expressed, but its expression can be induced by treatment with PMA, TNF-~, and in T cell lines by HSV-1 infection (Vlach & Pitha 1992a, b; Popik & Pitha, 1993) .
To determine whether HMBA can activate expression of HIV-1 provirus, the ACH-2 and U1 cells were treated with two different concentrations of HMBA for 12 and 36 h, respectively, and the cell lysates were analysed by Western blotting for the presence of HIV-1 proteins (Fig.  1) . The elevated levels of HIV-l-specific proteins could be readily detected at 12 h after stimulation with both the low (1 mM) and high (5 mM) concentrations of HMBA, indicating that HMBA can activate the expression of latent HIV-1 provirus in both T cells and monocytes. . One-hundredgg of protein lysate was separated by 10% SDS PAGE, transferred onto a nitrocellulose membrane and the HIVl-specific proteins were detected using antiserum from an AIDS patient as described (Vlach & Pitha, 1992b) . Lanes 1 and 6, untreated cells. Positions of HIV-1 proteins p55, p24 and p17 as well as M~ standards are indicated.
Since the induction was more efficient with 5 mN-HMBA, we used this concentration for further experiments. To determine whether the increased levels of HIV-l-specific proteins in HMBA-treated cells correlate with the increase in the relative levels of viral RNAs, we analysed the HIV-1 transcripts by S1 nuclease analysis using the riboprobe spanning the region of HIV-1 sequences between the cap site and nt + 80 (HindIII site). RNA was prepared from ACH-2 and U1 cells at 0 1, 3 and 5 h after treatment with 5 mM-HMBA. As a control, cells were treated for 5 h with the phorbol ester PMA. Fig. 2 shows that the increase of HIV-1 transcription occurs as early as 3 h after the treatment in ACH-2 cells, whereas in U 1 cells the response is faster and an increase in transcription occurred within 1 h. To determine whether the HMBA-mediated trans-activation can occur in the absence of the tat trans-activation, we examined the effect of H M B A on the induction of the tat-defective HIV-1 provirus in C E M R 7 / n e o cells. Interestingly, the effect of H M B A in CEMR7/neo cells was nearly negligible, indicating that the H M B A induction is not effective in the absence of tat trans-activation (Fig. 2) . Since the activation of fl-globin genes by H M B A in MELC does not require protein synthesis (Campbell et al., 1990) , we examined whether the activation of HIV-1 provirus in ACH-2 cells is also independent of cellular =¢, being elevated (Fig. 3, lanes 3 and 4) . Thus, in the HMBA-and CHX-treated cells, the expression of HIV-1 provirus has the rev-phenotype. Since HMBA does not cause significant changes in HIV-1 transcription of tat-defective provirus in CEMRT/neo cells, it appears that synthesis of HIV-1 regulatory Tat proteins is necessary for HMBA to induce latent provirus.
Determination of the minimal promoter region of HIV-1 LTR required for HMBA-mediated induction
To determine which element in HIV-1 LTR confers the inducibility by HMBA, plasmids containing 5' deletion mutants of HIV-1 LTR inserted in front of the CAT reporter gene were used. The mutants included the HIV(104)CAT construct, lacking the negative regulatory element (NRE) ofHIV-1 LTR (nt -104 ofHIV-1 LTR), the construct HIV(83)CAT which has a deleted NF-KB enhancer ( n t -8 3 ) and HIV(57)CAT which has the HIV-1 LTR sequences deleted from NRE to the Spl sites (nt -57). These plasmids were transfected into either A3.01 or ACH-2 cells. We used both cell lines in order to compare the characteristics of induction in the presence (ACH-2) and absence (A3.01) of Tat. The results (Fig. 4) showed that, in ACH-2 cells, HMBA is about as efficient an inducer of HIV-1 LTR as PMA; deletion of NRE (nt-104 HIV) slightly increased the responsiveness to the HMBA treatment in both ACH-2 and A3.01 cells. To confirm that the presence of KB enhancer is not necessary for the HMBA-mediated induction of HIV-1 LTR, we have transfected A3.01 cells with the plasmid pABtkCAT which contains the ~:B enhancer in front of the minimal tk promoter as well as with the p23tkCAT plasmid which contains both the KB enhancer and the LBP-1 binding sites ofHIV-1 (Vlach & Pitha, 1992a) . As shown in Fig. 7 , neither of these plasmids was inducible with HMBA. These results indicate that neither the NF~cB nor the LPB-1 binding sites can confer the responsiveness of the heterologous promoter to the treatment with HMBA.
To determine whether there is a cooperative interaction between PMA or HSV-1 and HMBA-mediated induction of HIV-1 LTR, we transfected the HIV-1 LTR CAT construct into ACH-2 cells, and then treated these cells with PMA or infected them with HSV-1 in the presence or absence of HMBA (Fig. 5) . Treatment of cells with PMA increased CAT activity 17-fold and the addition of HMBA did not result in significantly increased CAT activity; HMBA alone increased CAT activity 10-fold. Similarly, HSV-1 infection did not further increase CAT activity in cells stimulated with HMBA. These data suggest that HMBA effectively induces the poorly expressed HIV-1 LTR, but not the LTR that has been activated by PMA or HSV-1 infection. Fig. 6 . Binding of nuclear proteins to the enhancer element of HIV-1 LTR. Nuclear extracts were prepared from untreated ACH-2 cells (lane t) or cells treated with 5 mM-HMBA for 2 h (lane 2) or 6 h (lane 3) or with PMA (50 ng/ml) for 2 h (lane 4) or 6 h (lane 5). The DNA probe used for the electrophoretic mobility shift assay is the ScaI ( n t -139)/ DdeI ( n t -38) fragment of HIV-1 LTR (clone NL-4-3), containing NFxB and Spl sites. After incubation of the probe with the nuclear extracts, the complexes were resolved by native 4 % PAGE. The arrow indicates complex between NF-xB proteins and the probe.
Analysis of binding of nuclear factors to HIV-1 enhancer/promoter elements during HMBA induction
The activation of HIV-1 LTR transcription by extracellular stimuli is generally associated with the binding of nuclear factors to the enhancer region, especially to the NF4cB binding site as seen in TNF-~-or PMA-treated cells and to other regions of HIV-1 LTR promoter such as the LBP-1 region in HSV-l-infected cells. Using DNA probes that correspond to NRE ( n t -3 4 2 to -139), enhancer region (nt -1 3 9 to -3 8 ) and leader sequence ( n t -4 to +80), we were not able to detect any induction-specific binding or altered binding pattern in HMBA-treated cells (data not shown). Also, no changes in the binding pattern were observed when the oligonucleotide containing the Spl sites (nt -8 0 to -3 8 ) of HIV-1 LTR was used as a probe. In contrast, the extract from PMA-treated cells used as a control showed formation of a specific band with the oligonucleotide corresponding to the enhancer region (nt -139 to -38), indicating NF-xB-specific binding (Fig. 6) .
Response of other genes to HMBA in T cells
In order to relate the activation of HIV-1 in T cells to the known effect of HMBA in the cells studied previously, we analysed the expression of several cellular genes and transfected plasmids containing various viral promoters 5' of the CAT genes to determine whether there is any common pathway in the activation of HIV-1 provirus and other cellular genes. It has been shown that in MELC, HMBA-induced differentiation is accompanied by a decrease in the relative levels of the myc and myb proto-oncogene transcripts (Lachman et al., 1984; Ramsay et al., 1987) . Analysis of the levels of c-myc and c-myb RNAs in ACH-2 and U1 cells has shown a rapid decrease after HMBA treatment (data not shown). As in MELC, down-regulation of c-myc and c-myb expression did not require protein synthesis. Since the regulation of the HIV-1 promoter and that of the promoters of genes coding for inflammatory lymphokines show many similarities, we analysed the levels of interleukin (IL)-I and IL-6 mRNAs in HMBA-treated cells. However, no IL-1 and IL-6 transcripts could be detected in ACH-2 cells stimulated with HMBA for as long as 9 h (data not shown). We also tested the response of several viral promoters to HMBA-mediated stimulation in ACH-2 cells. Using hybrid plasmids in which expression of the CAT gene was under the control of the SV40 early promoter region or promoters of the HSV-1 IE genes ICPO and ICP4, we examined the ability of HMBA to enhance expression of CAT gene in transiently transfected ACH-2 cells. The results show (Fig. 7) that HMBA increased activity of the ICPO and ICP4 promoter regions by about two-to threefold, but did not stimulate the expression of the SV40 early promoter. The inability of HMBA to stimulate the SV40 early promoter as well as murine leukaemia virus LTR in MELC was observed previously (Campbell et al., 1990) . The plasmid pSP1CAT1, containing the Spl sites from the HIV-1 LTR inserted 5' of the minimal tk promoter, was not inducible by HMBA treatment (Fig. 7) , indicating that the Sp 1 sites alone are not able to confer inducibility by HMBA.
Discussion
In this paper, we have shown that the polar compound HMBA activates transcription of HIV-1 provirus in both T cells and monocytes. Melloni et al. (1987) have previously shown that, in MELC, HMBA induces the appearance of a soluble form of protein kinase C and therefore we expected that HMBA, like other protein kinase C activators, may activate HIV-1 provirus by an increased binding of NF-KB-specific trans-activators. Deletion analysis, however, has shown that the response ofHIV-1 LTR to HMBA occurred in the absence of NF-KB binding sites and, instead, the induction required the Sp 1 sites and promoter sequences downstream of the Sp 1 elements. Although the NF-xB sequences do not seem to be essential for virus replication (Leonard et al., 1989; Ross et al., 1991) , the lack of requirement for the NF-tcB binding in HMBA-mediated induction of HIV-1 provirus is surprising because this region is essential for activation ofHIV-1 LTR by a majority of extracellular stimuli (e.g. TNF-cq PMA, Tax, anti-CD4, HSV-1). Accordingly, these stimuli enhance binding of NF-~cB-specific nuclear proteins to the NF-~cB DNA sequence present in the enhancer of HIV-1 LTR, whereas no increase in the NF~cB-specific binding could be detected in HMBA-treated ACH-2 and U1 cells. The requirement for the Spl binding site and the downstream sequence for the HMBA-mediated induction somewhat resembles the induction of HIV-1 LTR by herpesvirus infection. We have shown that HSV-1 infection induces binding of nuclear protein HLP-1 to the LPB-1 binding site of the leader sequence and that this sequence alone can confer inducibility by HSV-1 (Vlach & Pitha, 1992a) . However, we have no evidence that HLP-1 is involved in stimulation of HIV-1 LTR by HMBA, since binding of HLP-1 was not detected in HMBA-treated cells and the multiple copies of LBP-1 sequence were not able to confer inducibility by HMBA.
Interestingly, a number of other, unrelated, promoters are also stimulated by HMBA. HMBA was shown to stimulate a rapid increase in the expression of ~-, fl-and 7-globin genes in MELC (Lachman et al., 1984; Ramsay et al., 1987; Campbell et al., 1990 ) and we have found that the expression of HSV-1 IE genes ICPO and ICP4 was increased by about threefold in HMBA-treated cells (see also McFarlane et al., 1992) . Interestingly, the strongly expressed viral promoters, such as SV40 early promoter or Moloney murine leukaemia virus LTR, are not inducible by HMBA. The regions of the human ~-and fl-globin promoters that are sufficient for inducibility by HMBA include the CAAT and TATA boxes, but otherwise these regions show very little sequence homology with the -53 to + 1 nt sequence of HIV-1 LTR. No obvious sequence homology can also be found between the -53 to + 1 region of HIV-1 LTR and the promoters of the 1CPO and ICP4 genes. These results, as well as the fact that in gel retardation assays we could not detect any difference between the binding of nuclear proteins from the untreated and HMBA-treated cells, indicate that it is unlikely that HMBA induces binding of a sequence-specific nuclear protein and suggest that the induction involves modification of one of the factors of the basic transcription machinery (Campbell et al., 1990) . There are several indications that, in contrast to other stimuli such as PMA, TNF-~ or HSV-1, the HMBA-mediated trans-activation requires the presence of Tat protein. Firstly, the latent HIV-1 provirus lacking a functional tat gene could not be induced by HMBA; secondly, in the absence of de novo synthesis of Tat protein in CHX-treated cells, the activation of the HIV-1 provirus by HMBA was inhibited; thirdly, HMBA did not significantly induce the HIV-1 LTR CAT plasmid in A3.01 cells. However, removal of NRE and KB enhancer increased activation of HIV-1 LTR by HMBA in the absence of Tat. This finding might coincide with the recent report from Zeichner et al. (1992) that linker scanning mutations within NRE affected the activity of HIV-1 LTR induced by HMBA.
The observation that HMBA can up-regulate the expression of HIV-1 provirus by an NF-tcB-independent mechanism indicates the existence of a regulatory pathway(s) circumventing the requirement for the induction of NF-KB and other DNA-specific binding nuclear proteins previously detected in cells stimulated with cytokines or infected with HSV-1. Existence of an alternative pathway for the HIV-1 LTR induction was also recently suggested by Sakaguchi et al. (1991) who showed the NF-KB-independent stimulation of HIV-1 LTR by mitogens. As in this study, the induction element(s) was localized downstream of nt -70. These authors suggested that the induction is mediated by a general transcriptional component, possibly TFIID factor binding to the TATA element. Finally, the observation that this drug can activate the HIV-1 provirus may have important implications for cancer treatment of HIV-l-positive patients. HMBA is being evaluated in phase 1 studies, as a potential anticancer drug (Marks & Rifkind, 1989) , and it is likely that the ability to induce HIV-1 expression is not unique to HMBA but may also apply to the other cytotoxic drugs presently used for treatment of the human neoplastic diseases. It may be necessary, therefore, to evaluate chemotherapeutic agents carefully for their ability to activate HIV-1 provirus before these drugs are used for treatment of neoplasia in AIDS patients.
